pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

807 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT782Endpoints585BioPharma Dive224onclive165BioSpace57Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • The Supreme Court won't take up drugmakers' IRA cases
    The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca…
    Endpoints · 2mo ago↗ source
  • Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
    Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent cli…
    Endpoints · 2mo ago↗ source
  • FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
    One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...
← prev
page 19 of 33
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]>
    <![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer]]>
    <![CDATA[Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years]]>
    <![CDATA[Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC]]>
    <![CDATA[A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen. ]]>
    onclive · 2mo ago↗ source
  • Makary resigns; Biogen reports Alzheimer’s data; and more
    Welcome back to Endpoints Weekly. The biggest news this week was Marty Makary’s resignation from his role as FDA Commissioner. The announcement came days after reports emerged that President Donald…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCC]]>
    <![CDATA[Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer]]>
    <![CDATA[The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer]]>
    <![CDATA[Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma]]>
    <![CDATA[Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC]]>
    <![CDATA[Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source
  • CDER chief Høeg fired from FDA as other top roles turn over
    The leader of the FDA's drug division, Tracy Beth Høeg, is expected to depart, as part of a broad shakeup at the top of the agency after the exit of now-former Commissioner Marty Makary, according ...
    Endpoints · 2mo ago↗ source
  • <![CDATA[Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial]]>
    <![CDATA[Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC]]>
    <![CDATA[Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?]]>
    <![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC]]>
    <![CDATA[Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.]]>
    onclive · 2mo ago↗ source
  • Biopharma M&A maintains strength even as large deals wane
    Biopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: meg…
    Endpoints · 2mo ago↗ source
  • Amgen expands crackdown on what it says is misuse of 340B program
    Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud…
    Endpoints · 2mo ago↗ source
  • <![CDATA[FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer]]>
    <![CDATA[The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS]]>
    <![CDATA[TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and Cancer]]>
    <![CDATA[Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.]]>
    onclive · 2mo ago↗ source
  • Candel reports prostate cancer drug's long-term data ahead of FDA filing
    Candel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…
    Endpoints · 2mo ago↗ source
  • Post-Hoc Live: Makary's out at FDA and what comes next
    Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. Makary was scheduled to sit down with senior reporter Max Bayer this week at ...
    Endpoints · 2mo ago↗ source